SCHEMBL4083976

SCHEMBL4083976

CCCNC(=O)c1c(-c2cccs2)csc1NC(=O)C12CC3CC(CC1C3)C2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.55
CNR1 P21554 2/20 0.55
TP53 P04637 3/20 0.46
POLB P06746 1/20 0.46
KDM4E B2RXH2 5/20 0.42
HPGD P15428 4/20 0.42
HSD17B10 Q99714 1/20 0.42
NPSR1 Q6W5P4 5/20 0.42
ALDH1A1 P00352 3/20 0.42
HIF1A Q16665 2/20 0.42
MAPT P10636 4/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
KMT2A Q03164 1/20 0.41
HTT P42858 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PPARG P37231 1/20 0.40
NCOA2 Q15596 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4080614 0.87 CNR2 (0.57) CNR2CNR1TP53POLBKDM4E
SCHEMBL4092608 0.85 CNR2 (0.54) CNR2CNR1TP53POLBHPGD
SCHEMBL4085564 0.85 MAPT (0.56) CNR2TP53POLBKDM4EHPGD
SCHEMBL4095706 0.84 TP53 (0.64) CNR2TP53POLBKDM4EHPGD
SCHEMBL3808536 0.83 CNR2 (0.66) CNR2CNR1TP53HPGDMEN1
SCHEMBL4084439 0.83 CNR2 (0.66) CNR2CNR1TP53HPGDMEN1
SCHEMBL3806688 0.80 CNR2 (0.60) CNR2CNR1KDM4EHPGDALDH1A1
SCHEMBL4080886 0.80 CNR2 (0.60) CNR2CNR1KDM4EHPGDALDH1A1
SCHEMBL4084484 0.79 CNR2 (0.60) CNR2CNR1TP53KDM4EHPGD
SCHEMBL3806301 0.79 CNR2 (0.60) CNR2CNR1TP53KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 CNR2 2/4885CNR1 1/4885TP53 4856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.